Big Rock Partners Acquisition Corp. (BRPA)
BRPA Price and Sentiment
BRPA Latest news
Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx2021-05-21 18:40
Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (Nasdaq:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.
The stock price of Big Rock Partners Acquisition (NASDAQ: BRPA) increased by 88.01%. This is why it happened.
NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia2021-04-28 14:12
RADNOR, Pa. and TBLISI, Georgia, April 28, 2021 /PRNewswire/ -- NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI (aviptadil acetate) for critically-ill citizens of Georgia with COVID-19 Respiratory Failure.
Big Rock Partners Acquisition Corp (NASDAQ: BRPA) shares are trading higher after the company's SPAC merger target, NeuroRx, on Monday confirmed dosing of the first patient in a Phase 3 trial of ZYESAMI was announced by the NIH last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19, will study ZYESAMI to treat severely ill COVID-19 patients.
Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team2021-04-26 09:35
RADNOR, Pa., April 26, 2021 /PRNewswire/ -- Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week.
RADNOR, Pa., April 19, 2021 /PRNewswire/ -- The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis.
Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal2021-04-07 18:35
NEW YORK, NY / ACCESSWIRE / April 7, 2021 / Big Rock Partners Acquisition Corp. (Nasdaq:BRPA) ("Big Rock") today clarified the procedure for stockholder redemptions in connection with Big Rock's special meeting of stockholders called for the purpose of approving an amendment to Big Rock's amended and restated certificate of incorporation to extend the date by which Big Rock has to consummate its initial business combination from April 23, 2021 to May 24, 2021 (the "extension amendment proposal"). Proxy statements are being mailed to Big Rock stockholders of record as of March 31, 2021.
Good morning and welcome to the stock market today! The Ever Given is free, Wall Street is caught up in a fire sale tizzy and cryptos are climbing again.
After taking a hit in recent weeks, RLFTF stock investors got some good news on its respiratory failure treatment collaboration with BRPA target NeuroRx. The post RLFTF Stock: Why Relief Therapeutics and BRPA Stock Are Soaring Today appeared first on InvestorPlace.
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure2021-03-26 09:35
RADNOR, Pa., March 26, 2021 /PRNewswire/ -- NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 respiratory failure (www.clinicaltrials.gov 04311697).